Y Intercept Hong Kong Ltd Has $230,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Y Intercept Hong Kong Ltd reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 67.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,768 shares of the company’s stock after selling 19,926 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Dyne Therapeutics were worth $230,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Creative Planning boosted its position in shares of Dyne Therapeutics by 41.5% during the 3rd quarter. Creative Planning now owns 10,605 shares of the company’s stock valued at $381,000 after acquiring an additional 3,111 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the period. US Bancorp DE boosted its holdings in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Hanseatic Management Services Inc. bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $258,000. Finally, Privium Fund Management B.V. grew its stake in shares of Dyne Therapeutics by 7.1% in the 3rd quarter. Privium Fund Management B.V. now owns 15,016 shares of the company’s stock valued at $539,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard William Scalzo sold 1,455 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the transaction, the senior vice president now directly owns 127,078 shares in the company, valued at $3,573,433.36. The trade was a 1.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,387 shares of company stock valued at $142,789. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $11.89 on Wednesday. The stock has a market capitalization of $1.21 billion, a PE ratio of -3.34 and a beta of 1.11. The company has a 50 day moving average price of $16.75 and a 200 day moving average price of $27.26. Dyne Therapeutics, Inc. has a fifty-two week low of $11.62 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on DYN shares. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, February 28th. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Finally, HC Wainwright reduced their price target on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.64.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.